SCHEMBL25012725

SCHEMBL25012725

COCCOC(=O)[C@H](C)NP(=O)(Oc1ccc(C(C)(C)C)cc1)Oc1c(F)c(F)c(F)c(F)c1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTN3A1 O00481 6/20 0.38
▸ MAPT P10636 2/20 0.36
▸ MEN1 O00255 5/20 0.35
▸ KMT2A Q03164 5/20 0.35
▸ NPC1 O15118 3/20 0.35
▸ ALDH1A1 P00352 4/20 0.35
▸ LMNA P02545 2/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ APEX1 P27695 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ RECQL P46063 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ NR1H4 Q96RI1 2/20 0.35
▸ RAB9A P51151 3/20 0.34
▸ L3MBTL1 Q9Y468 2/20 0.34
▸ EPHX2 P34913 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24148980 0.92 MAPT (0.38) BTN3A1MAPTMEN1KMT2ANPC1
SCHEMBL30269864 0.91 BTN3A1 (0.35) BTN3A1MEN1KMT2ANPC1LMNA
SCHEMBL24148909 0.90 BTN3A1 (0.43) BTN3A1MAPTMEN1KMT2ANPC1
SCHEMBL24149362 0.90 BTN3A1 (0.34) BTN3A1MAPTMEN1KMT2ANPC1
SCHEMBL24149229 0.89 BTN3A1 (0.41) BTN3A1MAPTMEN1KMT2ANPC1
SCHEMBL24149402 0.88 BTN3A1 (0.36) BTN3A1MAPTMEN1KMT2ANPC1
SCHEMBL24149166 0.88 BTN3A1 (0.34) BTN3A1MEN1KMT2ANPC1ALDH1A1
SCHEMBL25013459 0.88 HDAC3 (0.37) BTN3A1MAPTMEN1KMT2AALDH1A1
SCHEMBL24148709 0.88 BTN3A1 (0.37) BTN3A1MAPTMEN1KMT2ANPC1
SCHEMBL24148721 0.88 BTN3A1 (0.37) BTN3A1MAPTMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260035394-A1 1`-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF GILEAD SCIENCES INC (US) 2026-02-05 — — US disclosed
US-12404289-B2 1′-cyano nucleoside analogs and uses thereof GILEAD SCIENCES, INC. (US) 2025-09-02 — — US disclosed
US-20240287109-A1 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF GILEAD SCIENCES, INC. 2024-08-29 — — US disclosed
US-11939347-B2 1′-cyano nucleoside analogs and uses thereof GILEAD SCIENCES, INC. (US) 2024-03-26 — — US disclosed
EP-4172160-A2 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-05-03 — — EP disclosed
US-20230040586-A1 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF GILEAD SCIENCES, INC. 2023-02-09 — — US disclosed
US-20230040586-A1 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF GILEAD SCIENCES, INC. 2023-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287109-A1 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF TYMP, PNP, DUT BTN3A1 3427/4885MAPT 4362/4885MEN1 1799/4885
US-12404289-B2 1′-cyano nucleoside analogs and uses thereof TYMP, PNP, DUT BTN3A1 3685/4885MAPT 4424/4885MEN1 2031/4885
US-20230040586-A1 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF TYMP, PNP, DUT BTN3A1 3427/4885MAPT 4362/4885MEN1 1799/4885
US-11939347-B2 1′-cyano nucleoside analogs and uses thereof TYMP, PNP, DUT BTN3A1 3685/4885MAPT 4424/4885MEN1 2031/4885
US-20260035394-A1 1`-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF PNP, SLC28A1, SLC29A1 BTN3A1 3686/4885MAPT 3305/4885MEN1 4014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback